Image For Activity Cover
HFSA Board Certification Review 2020: AHFTC
General Meeting Information
The HFSA Board Certification Review 2020 is comprised of renowned heart failure experts presenting curriculum from the HFSA Virtual Board Certification Review 2020 (presented on July 24, July 31-August 1, 2020). This course has been tailored to the actual ABIM Advanced Heart Failure and Transplant Cardiology Certification Examination.
Intended Audience
The HFSA Board Certification Review 2020 is designed for physicians who are preparing to take the ABIM Advanced Heart Failure and Transplant Cardiology Board Certification Exam.
Learning Objectives

Upon completion of the activity, participants will demonstrate improved competence and ability to: 

For the Certification Examination in Advanced Heart Failure and Transplant Cardiology:

  1. Identify gaps in knowledge about advanced heart failure and transplant cardiology
  2. Focus study efforts on filling identified knowledge gaps
  3. Practice for the certification examination with ABIM-style multiple-choice test questions

For Clinical Practice:

  1. Describe the epidemiology of heart failure, including environmental factors, and implement strategies for the prevention of heart failure
  2. Describe the pathophysiology of heart failure, including normal physiology and compensatory and maladaptive mechanisms
  3. Assess and follow the patient with acute or advanced heart failure, using non-invasive and invasive tests and biomarkers.
  4. Implement guideline-based therapy for patients with chronic heart failure, including pharmacologic agents; non-pharmacologic options, such as diet and exercise; and implantable devices
  5. Implement appropriate care strategies for patients undergoing chemotherapy or with pulmonary hypertension, heart failure with preserved ejection fraction, or cardiorenal syndrome.
  6. Manage comorbidities in patients with chronic heart failure, including sleep disordered breathing, anemia, and depression
  7. Implement strategies for effective disease management of the patient with advanced heart failure, including palliative care and transition to outpatient care
  8. Provide peri-operative management of heart failure patients undergoing cardiac transplantation or implantation of a mechanical circulatory device
  9. Concise presentations by national experts will focus on blueprint content and will be augmented by board-review type questions posed using an audience-response system.
Co-Chairs & Planning Committee
  • Akshay S. Desai, MD, MPH, FHFSA - Brigham and Women’s Hospital, Boston, MA
  • Jonathan Rich, MD, FHFSA - Northwestern University, Feinberg School of Medicine, Chicago, IL
  • Nancy Sweitzer, MD, PhD, FHFSA - University of Arizona, Tucson, AZ
Course Details

Heart Failure Fundamentals

Heart Failure Epidemiology and Risk Factors

Sadiya Khan

Pathophysiology I: Cellular and Energetic Considerations

Daniel Burkhoff

Pathophysiology II: Hemodynamic, Structural, and Neurohormonal Considerations

Daniel Burkhoff

Diagnosis and Clinical Assessment

Mark Drazner

Device Therapy in Heart Failure

Liviu Klein

Cardio-Oncology for the HF boards

Anju Nohria

Clinico-Pathologic Correlates in Heart Failure/ Images for the Heart Failure Boards

Jon Lomasney

   

Welcome & HFSA Introduction – Day 1

 

Welcome & HFSA Introduction

Akshay Desai, John Barnes 

 

 

Cardiac Transplantation

Moderator: Nancy Sweitzer

Advanced Heart Failure:  Defining the Phenotype and Patient Selection for Advanced Therapies 

Nancy Sweitzer

Immunology: The Basics, PRA, Sensitization, Crossmatch

Sean Pinney

Rejection: Cellular and Antibody Mediated

Sean Pinney

Managing Immunosuppression and Drugs

Michelle Kittleson

Heart Transplant, Clinical Outcomes and Complications

Michelle Kittleson

   

Key Issues in HF Management

Moderator: Jonathan Rich

Hemodynamics in HF I

James Fang

Hemodynamics in HF II

James Fang

Drug Therapy for Chronic HF I: Focus on established therapies (ACE/ARB/Beta-blocker/MRA/Digoxin/Hydralazine+Nitrates)

Clyde Yancy

Drug Therapy for Chronic HF II: Focus on newer therapies (Sacubitril/Valsartan, Ivabradine, SGLT2 inhibitors)

Mark Drazner

HFpEF: Epidemiology, Risk Factors, Diagnosis, Management (for the boards)

Sanjiv Shah

Management of the Hospitalized HF Patient

Meredith Brisco-Bacik

Management of Common Arrhythmias in HF (including AF)

Liviu Klein

Management of Comorbidities in Heart Failure

Meredith Brisco-Bacik

   

Specific Heart Failure Syndromes

Moderator: Jonathan Rich

Specific Etiologies of HF I: Common Etiologies (CAD, ETOH, Peripartum, Myocarditis)

Akshay Desai

Specific Etiologies of HF II: Inherited HF syndromes (including HCM, ARVC, and LVNC)

Jane Wilcox

Specific Etiologies of HF III: Infiltrative Disorders and Restrictive Cardiomyopathy (Amyloidosis, Sarcoidosis, Hemochromatosis, Fabry)

Sanjiv Shah

   

Q&A Panel I

 

Q&A ---- Overview

Akshay Desai, Nancy Sweitzer, Jonathan Rich 

   

Welcome & HFSA Introduction

 

Welcome & HFSA Introduction

Akshay Desai, John Barnes 

 

 

Shock/MCS

Moderator: Nancy Sweitzer

Cardiogenic Shock Management

Nancy Sweitzer

MCS I:  Durable MCS Devices and Outcomes

Joseph Rogers

MCS II: Temporary Support Devices and ECMO for the Boards

Jennifer Cowger

MCS III: MCS Complications and Patient Management

Jennifer Cowger

MCS IV: Troubleshooting (with HARVI)

Daniel Burkhoff, Jennifer Cowger, Joseph Rogers, Nancy Sweitzer

   

Special Topics in HF

Moderator: Akshay Desai

Assessment of Functional Capacity including cardiopulmonary exercise testing

Gregory Lewis

Adult Congenital Heart Disease for the HF Specialist

Eric Krieger

Issues in Chronic HF Disease Management (Biomarkers, Remote Monitoring, Lifestyle Interventions)

Akshay Desai

Management of Valvular Heart Disease in Heart Failure (including functional MR, low gradient AS, tricuspid regurgitation)

Jane Wilcox

Pulmonary Hypertension

Jonathan Rich

   

Q&A Panel II

 

Q&A ---- Overview

Akshay Desai, Nancy Sweitzer, Jonathan Rich 

 

Faculty Listing
  • Meredith Brisco-Bacik, MD, MSCE - The Lewis Katz School of Medicine at Temple University, Philadelphia, PA
  • Daniel Burkhoff, MD, PhD - Columbia University, New York, NY
  • Jennifer Cowger, MD, MS - Wayne State University, Detroit, MI
  • Akshay S. Desai, MD, MPH, FHFSA - Brigham and Women’s Hospital, Boston, MA
  • Mark Drazner, MD, MSc, FHFSA - University of Texas Southwestern Medical Center, Dallas, TX
  • James Fang, MD, FHFSA - University of Utah, Salt Lake City, UT
  • Sadiya Khan, MD, MSc - Northwestern University Feinberg School of Medicine, Chicago, IL
  • Michelle Kittleson, MD, PHD - Cedars Sinai Medical Center, Los Angeles, CA
  • Liviu Klein, MD, MS - University of California, San Francisco, San Francisco, CA
  • Eric Krieger, MD - University of Washington School of Medicine, Seattle, WA
  • Gregory Lewis, MD - Massachusetts General Hospital, Boston, MA
  • Jon Lomasney, MD - Feinberg School of Medicine of Northwestern University, Chicago, IL
  • Anju Nohria, MD, MSc - Brigham and Women’s Hospital, Boston, MA
  • Sean Pinney, MD - The Mount Sinai Hospital, New York, NY
  • Jonathan Rich, MD, FHFSA - Northwestern University, Feinberg School of Medicine, Chicago, IL
  • Joseph Rogers, MD - Duke University, Durham, NC
  • Sanjiv Shah, MD - Northwestern University Feinberg School of Medicine, Chicago, IL
  • Nancy Sweitzer, MD, PhD, FHFSA - University of Arizona, Tucson, AZ
  • Jane Wilcox, MD, MSc, FHFSA - Bluhm Cardiovascular Institute, Chicago, IL
  • Clyde W. Yancy, MD, MSc, FHFSA - Bluhm Cardiovascular Institute, Chicago, IL
Accreditation Statement

Credit Designation

This HFSA Board Review Certification Course has been designed based on the competencies identified with practice in the area of Advanced Heart Failure and Transplant Cardiology.

These competencies include epidemiology, causes and management of patients with HF, management of hospitalized patients, management of comorbidities, cardiac surgery in HF, medical management of the heart transplant patient and patients with mechanical circulatory support, and evaluation and management of patients with pulmonary arterial hypertension.

Physicians

The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

 

The Heart Failure Society of America designates this live activity for a maximum of 19 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Successful completion of this CME activity, which includes participation in the post course evaluation with a passing score of 80% on the posttests, enables the participant to earn up to 19 MOC points in the Maintenance of Certification (MOC) program. 

Participants of the live virtual activity wishing to claim MOC must complete requirements no later than Monday, November 23, 2020. This will allow time for the HFSA, the CME provider, to submit the participant’s completion information to ACCME for the purpose of granting ABIM MOC credit.

Faculty and Accreditor Disclosures

The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 12 months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.

 

Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.

 

The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest:

 

  • Meredith Brisco-Bacik, MD, MSCE
  • Mark Drazner, MD, MSc, FHFSA
  • Sadiya Khan, MD, MSc
  • Michelle Kittleson, MD, PHD
  • Eric Krieger, MD
  • Gregory Lewis, MD
  • Jon Lomasney, MD
  • Joseph Rogers, MD
  • Sanjiv Shah, MD

 

The following faculty and/or accreditors with ability to control content for this activity have listed the below disclosures:

 

  • Daniel Burkhoff, MD, PhD – Research Grant: Abiomed (Education),Ancora Medical, Tenax,Fire 1; Ownership Interest: PV Loops LLC (non-relevant financial relationship); Consultant-Advisory Board: BackBeat Medical, CardioDyme, Janssen Pharmaceuticals, Medtronic, Axon THerapies; Corvia, PVLoops LLC
  • Jennifer Cowger, MD, MS – Research Grant: Abbott, Medtronic; Speaker-Honoraria: Abbott, Medtronic; Consultant-Advisory Board: Abbott, Medtronic
  • Akshay Desai, MD, MPH, FHFSA – Research Grant: Alnylam; AstraZeneca; Novartis; Consultant-Advisory Board: Abbott; Alnylam; AstraZeneca; Amgen; Biofourmis; Noston Scientific; Boehringer-Ingelheim; Corvidia; DalCor Pharma; Merck; Novartis; Relypsa; Regeneron
  • James C. Fang, MD, FHFSA – Consultant/Advisory Board: Novartis, Amgen, Capricor, Johnson & Johnson, American Heart Association, NIH, AstraZeneca, BI/Lily, Abbott
  • Liviu Klein, MD, MS – Consultant-Advisory Board: Boston Scientific (Steering Committee); Medtronic (Steering Committee)
  • Anju Nohria, MD, MSc – Research Grant: Amgen, Inc.; Consultant-Advisory Board: Takeda Oncology
  • Sean Pinney, MD – Speaker-Honoraria: CareDX; Consultant-Advisory Board: CareDx
  • Jonathan D. Rich, MD, FHFSA – Consultant-Advisory Board: Bayer
  • Nancy Sweitzer, MD, PhD, FHFSA – Research Grant: Merck, Novartis; Consultant-Advisory Board: Myokardia
  • Jane Wilcox, MD, MSc, FHFSA – Speaker-Honoraria: Medtronic; Consultant-Advisory Board: Cytokinetics
  • Clyde Yancy, MD, MSc, FHFSA – Financial Disclosure: Spousal employment at Abbott, Inc.

OFF-LABEL DISCLOSURE

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

Summary
Availability: On-Demand
Cost: Member: $799.00
Non-Member: $899.00
Credit Offered: 19 CME Credits
19 MOC Points
Contains: 13 Courses
Powered by Oasis.